| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 1450 | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 441* | 2021 |
| Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment AC Bibby, S Tsim, N Kanellakis, H Ball, DC Talbot, KG Blyth, NA Maskell, ... European Respiratory Review 25 (142), 472-486, 2016 | 333 | 2016 |
| Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging PB Mark, N Johnston, BA Groenning, JE Foster, KG Blyth, TN Martin, ... Kidney international 69 (10), 1839-1845, 2006 | 320 | 2006 |
| Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension KG Blyth, BA Groenning, TN Martin, JE Foster, PB Mark, HJ Dargie, ... European heart journal 26 (19), 1993-1999, 2005 | 265 | 2005 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10320), 143, 2022 | 232 | 2022 |
| Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10289), 2049-2059, 2021 | 221* | 2021 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 215 | 2022 |
| Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension–targeted therapy: the EURO-MR Study AJ Peacock, S Crawley, L McLure, KG Blyth, CD Vizza, R Poscia, ... Circulation: Cardiovascular Imaging 7 (1), 107-114, 2014 | 186 | 2014 |
| NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension KG Blyth, BA Groenning, PB Mark, TN Martin, JE Foster, T Steedman, ... European Respiratory Journal 29 (4), 737-744, 2007 | 185 | 2007 |
| Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors AC Kidd, M McGettrick, S Tsim, DL Halligan, M Bylesjo, KG Blyth BMJ open respiratory research 5 (1), e000240, 2018 | 163 | 2018 |
| Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma L Au, E Hatipoglu, MR de Massy, K Litchfield, G Beattie, A Rowan, ... Cancer cell 39 (11), 1497-1518. e11, 2021 | 150 | 2021 |
| Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection. An effective and safe alternative to surgery F Piccolo, N Pitman, R Bhatnagar, N Popowicz, NA Smith, B Brockway, ... Annals of the American Thoracic Society 11 (9), 1419-1425, 2014 | 133 | 2014 |
| Effect of thoracoscopic talc poudrage vs talc slurry via chest tube on pleurodesis failure rate among patients with malignant pleural effusions: a randomized clinical trial R Bhatnagar, HEG Piotrowska, M Laskawiec-Szkonter, BC Kahan, ... Jama 323 (1), 60-69, 2020 | 110 | 2020 |
| Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial RJ Hallifax, E McKeown, P Sivakumar, I Fairbairn, C Peter, A Leitch, ... The Lancet 396 (10243), 39-49, 2020 | 88 | 2020 |
| Dose de-escalation of intrapleural tissue plasminogen activator therapy for pleural infection. The alteplase dose assessment for pleural infection therapy project N Popowicz, O Bintcliffe, D De Fonseka, KG Blyth, NA Smith, F Piccolo, ... Annals of the American Thoracic Society 14 (6), 929-936, 2017 | 88 | 2017 |
| The evolution of lung cancer and impact of subclonal selection in TRACERx AM Frankell, M Dietzen, M Al Bakir, EL Lim, T Karasaki, S Ward, ... Nature 616 (7957), 525-533, 2023 | 80 | 2023 |
| British thoracic society guideline for pleural disease ME Roberts, NM Rahman, NA Maskell, AC Bibby, KG Blyth, JP Corcoran, ... Thorax 78 (Suppl 3), s1-s42, 2023 | 75 | 2023 |
| Representative sequencing: unbiased sampling of solid tumor tissue K Litchfield, S Stanislaw, L Spain, LL Gallegos, A Rowan, D Schnidrig, ... Cell reports 31 (5), 2020 | 59 | 2020 |
| A multisystem, cardio-renal investigation of post-COVID-19 illness AJ Morrow, R Sykes, A McIntosh, A Kamdar, C Bagot, HK Bayes, KG Blyth, ... Nature medicine 28 (6), 1303-1313, 2022 | 56 | 2022 |
John E FosterHead of MR Physics Group, NHS Greater Glasgow and ClydeVerified email at nhs.net
